ARVN News and Press, Arvinas Inc. From 06/03/21

NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer...

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers

Arvinas went public at $16 on September 26, 2018. The stock zoomed to $92.77 on the early trial successes of its two oncology targets. and currently trades at $67.18. Pfizer has a cooperation with Arvinas, which the latter shows may deliver another $802 million potential revenue. ...

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D.,...

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New Haven, Con...

Arvinas (ARVN): Q1 GAAP EPS of -$0.84 misses by $0.04.Revenue of $5.54M (-11.2% Y/Y) beats by $1.45M.Press Release For further details see: Arvinas EPS misses by $0.04, beats on revenue

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corpora...

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) An...

Arvinas (ARVN) shares are poised to rise significantly thanks to a "data-rich" second half of the year, according to Cantor analyst Alethia Young.She is reiterating her overweight rating and is raising her price target to $140 from $121.Based on yesterday's closing price of $58.19, that repre...